Advertisement
News
Advertisement

Sunovion advances drug for bipolar disorder

Tue, 10/30/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Sunovion Pharmaceuticals Inc. said the U.S. Food and Drug Administration has accepted its applications to expand the indication of its schizophrenia drug, Latuda to be used as a treatment for bipolar disorder. One application requests approval for Latuda to be used in combination with other drugs, and the other requests an approval to be prescribed as a bipolar treatment on its own.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading